Literature DB >> 31452826

Undifferentiated carcinoma of the pancreas with osteoclast-like giant cells showing intraductal growth and intratumoral hemorrhage: MRI features.

Keisuke Sato1, Hiroshi Urakawa1, Keiko Sakamoto1, Emi Ito1, Yoshihiro Hamada2, Kengo Yoshimitsu1.   

Abstract

We report a case of undifferentiated carcinoma of the pancreas with osteoclast-like giant cells ocalized within the main pancreatic duct (MPD). A 61-year-old woman was referred to our hospital for evaluation of dilatation of the MPD that was detected on screening sonogram. Preoperative MR imaging revealed a small hypervascular tumor within the dilated MPD, showing high signal on R2* map and signal reduction on in-phase as compared to out-of-phase. R2* hyperintensity and in-phase signal reduction may be a characteristic feature of undifferentiated carcinoma of the pancreas with osteoclast-like giant cells, which indicates intratumoral hemorrhage even if they are small.

Entities:  

Keywords:  Chemical-shift imaging; Intraductal growth; Intratumoral hemorrhage; R2* map; Undifferentiated carcinoma of the pancreas with osteoclast-like giant cells

Year:  2019        PMID: 31452826      PMCID: PMC6704396          DOI: 10.1016/j.radcr.2019.07.020

Source DB:  PubMed          Journal:  Radiol Case Rep        ISSN: 1930-0433


Case report

A 61-year-old Japanese woman was referred to our hospital for further investigation of dilatation of the main pancreatic duct (MPD). Her past history included type-2 diabetes mellitus, hypertension, hyperlipidemia, hyperuricemia, gall bladder stone with adenomyomatosis, and fatty liver. She had been mostly asymptomatic and periodical screening ultrasonography (US) examination incidentally revealed dilated MPD. Screening US performed 2 years earlier was negative. Her family history was unremarkable. Laboratory data on admission was unremarkable, including serum amylase level, except for slightly elevated serum glucose (118 mg/dL) and HbA1c (6.8 %). IgG4 and tumor makers including carcinoembryonic antigen, carbohydrate antigen 19-9, and DUPAN-2 were all negative. Computed tomography (CT) revealed a polypoid lesion occupying the MPD lumen, measuring approximately 40 mm in length at the pancreas head and body. No calcification was seen. The major part of the lesion in the MPD of the pancreatic body showed apparent enhancement on the arterial dominant phase and subsequent washout on the equilibrium phase, but the part of the lesion in the MPD of the pancreatic head was weakly enhanced both on arterial phase and equilibrium phase (Fig. 1). The parenchyma of the pancreatic tail showed slight atrophy and prolonged enhancement with a dilated MPD, suggesting obstructive pancreatitis. Magnetic resonance imaging (MRI) using a 3 T MR system (Discovery MR750w 3.0 T, GE Healthcare, Milwaukee, WI) was performed for the pancreas lesion. On T2-weighted images (Fig. 2A) and diffusion-weighted image (not shown), the tumor was markedly hypointense. On R2* map obtained by iterative decomposition of water and fat with echo asymmetry and least-squares estimation (IDEAL) IQ, the tumor was hyperintense with mean R2* value of approximately 300 per second (Fig. 2B). The tumor showed apparent signal reduction on in-phase as compared to out-of-phase image of chemical shift MRI (Fig. 2C and D). The lesion exhibited intraluminal location within MPD, and the intraparenchymal component was hardly appreciated either on CT or MRI. The Fluorine 18-Fluorodeoxyglucose positron emission tomography combined with CT (18F-FDG-PET/CT) showed uptake of FDG at the pancreas lesion with the maximum standardized uptake value of 4.03 and no evidence of metastasis (Fig. 3). Endoscopic retrograde pancreatography and intraductal US demonstrated the tumor within MPD. Preoperative diagnosis of neuroendocrine tumor (NET) was made, and the patient underwent a pancreaticoduodenectomy along with resection of the spleen.
Fig. 1

Dynamic CT using total volume of 600 mg/kg iodine contrast medium, injected in 30 seconds. (A) Arterial phase transaxial image obtained 40 seconds after the commencement of contrast medium injection at the level of the lesion of the pancreatic body. Note a tubular lesion in the main pancreatic duct of the pancreatic body with homogeneous enhancement (arrow). (B) Atrial phase transaxial image at the level of the pancreatic head. The lesion shows less enhancement (arrow) as compared to (A). Thickened gallbladder wall with calcification (arrowhead) turned out to be adenomyomatosis at the surgery. (C) Equilibrium phase obtained 240 seconds after the commencement of contrast medium injection. The lesion shows apparent washout (arrow) and atrophied pancreas parenchyma of the pancreatic tail shows relatively strong enhancement to the normal pancreatic parenchyma, which indicates chronic obstructive pancreatitis (arrow heads).

Fig. 2

Magnetic resonance (MR) imaging of the pancreas. (A) Heavily T2-weighted image (repetition time [TR]/echo time [TE] = 6000/259.8 milliseconds). The pancreas lesion is illustrated as a hypointense nodule (arrow). Main pancreatic duct of the pancreas tail is dilated. (B) R2* map generated from IDEAL-IQ (TR/TE/FA = 7.4/3.2ms/3°, echo space 0.9, 3 echoes × 2). The lesion is depicted as a very hyperintense nodule. (C) Gradient-echo 2D T1-weighted out-of-phase chemical shift image (TR/TE/FA = 220.0/1.2/50°). The lesion shows intermediate to high signal intensity (arrow). (D) Gradient-echo 2D T1-weighted in-phase chemical shift image (TR/TE/FA = 220.0/2.5/50°). Apparent signal loss is seen in the lesion (arrow).

Fig. 3

Fluorine 18 Fluorodeoxyglucose (18FDG) positron emission tomography-computed tomography (PET-CT). Transaxial image through the level of the pancreas lesion. 18FDG uptake is increased in the lesion of the pancreatic body (arrow) and head (arrow head). The maximum standardized uptake value of the pancreas mass was 4.03. No other abnormal FDG uptake was seen.

Dynamic CT using total volume of 600 mg/kg iodine contrast medium, injected in 30 seconds. (A) Arterial phase transaxial image obtained 40 seconds after the commencement of contrast medium injection at the level of the lesion of the pancreatic body. Note a tubular lesion in the main pancreatic duct of the pancreatic body with homogeneous enhancement (arrow). (B) Atrial phase transaxial image at the level of the pancreatic head. The lesion shows less enhancement (arrow) as compared to (A). Thickened gallbladder wall with calcification (arrowhead) turned out to be adenomyomatosis at the surgery. (C) Equilibrium phase obtained 240 seconds after the commencement of contrast medium injection. The lesion shows apparent washout (arrow) and atrophied pancreas parenchyma of the pancreatic tail shows relatively strong enhancement to the normal pancreatic parenchyma, which indicates chronic obstructive pancreatitis (arrow heads). Magnetic resonance (MR) imaging of the pancreas. (A) Heavily T2-weighted image (repetition time [TR]/echo time [TE] = 6000/259.8 milliseconds). The pancreas lesion is illustrated as a hypointense nodule (arrow). Main pancreatic duct of the pancreas tail is dilated. (B) R2* map generated from IDEAL-IQ (TR/TE/FA = 7.4/3.2ms/3°, echo space 0.9, 3 echoes × 2). The lesion is depicted as a very hyperintense nodule. (C) Gradient-echo 2D T1-weighted out-of-phase chemical shift image (TR/TE/FA = 220.0/1.2/50°). The lesion shows intermediate to high signal intensity (arrow). (D) Gradient-echo 2D T1-weighted in-phase chemical shift image (TR/TE/FA = 220.0/2.5/50°). Apparent signal loss is seen in the lesion (arrow). Fluorine 18 Fluorodeoxyglucose (18FDG) positron emission tomography-computed tomography (PET-CT). Transaxial image through the level of the pancreas lesion. 18FDG uptake is increased in the lesion of the pancreatic body (arrow) and head (arrow head). The maximum standardized uptake value of the pancreas mass was 4.03. No other abnormal FDG uptake was seen. Macroscopically, polypoid whitish solid tumor with intratumoral hemorrhage, predominantly around the head of the pancreas, was noted within MPD (Fig. 4A and B). Histopathologically, the tumor was composed of a proliferation of mononuclear cells and multinucleated giant cells, admixed with hemosiderin deposits (Fig. 4C). There was a small ductal adenocarcinoma component as well. The tumor was located predominantly within the intraluminal space of MPD, associated with microscopic invasive foci to the parenchyma at the body of the pancreas (Fig. 4B). Immunohistochemical examination revealed multinucreated giant cells positive for CD68 staining. CD31 staining revealed abundant vascular space in the tumor. Ductal adenocarcinoma component was positive for MUC1, AB-PAS, and Cytokeratin 7. The final diagnosis of undifferentiated carcinoma of the pancreas with osteoclast-like giant cells (UCPOGC), T1N0M0, was thus made.
Fig. 4

Histopathological and macroscopic findings. (A) A gross appearance of the cut surface along the main pancreatic duct (MPD). A whitish lesion with intratumoral hemorrhage (arrows) is noted occupying the lumen of MPD. (B) H&E staining with low magnification shows the tumor protruding into the MPD lumen (arrows) and shows small tumor invasion to the surrounding parenchyma (arrowheads). (C) H&E staining with high magnification shows highly atypical mononuclear cells and multinuclear giant cells (arrows) with admixed hemosiderin (small brownish nodules).

Histopathological and macroscopic findings. (A) A gross appearance of the cut surface along the main pancreatic duct (MPD). A whitish lesion with intratumoral hemorrhage (arrows) is noted occupying the lumen of MPD. (B) H&E staining with low magnification shows the tumor protruding into the MPD lumen (arrows) and shows small tumor invasion to the surrounding parenchyma (arrowheads). (C) H&E staining with high magnification shows highly atypical mononuclear cells and multinuclear giant cells (arrows) with admixed hemosiderin (small brownish nodules). The patient received adjuvant chemotherapy with Tegafur, Gimeracil, and Oteracil Potassium (as known as TS-1) for 1 year. She is alive without evidence of local recurrence or distant metastasis 35 months after the surgery at the time of this writing.

Discussion

UCPOGC is a very rare tumor accounting for 2%-7% of all pancreatic cancers [1]. UCPOGC is initially described in 1968 by Juan Rosai as a variant of undifferentiated carcinoma [2]. Unlike the original undifferentiated carcinoma, which is very aggressive and frequently metastasizes to lymph nodes or other organs, UCPOGC is known to be less aggressive, the prognosis of which is better than invasive ductal carcinoma of the pancreas [3]. Clinical presentation of UCP is nonspecific, including abdominal pain, a palpable mass, weight loss, etc, and tumor markers including CA 19-9 elevate in about half of the patients [4], [5]. UCPOGC is usually large, moderately to highly hypervascular, and exophytic tumors with large areas of intratumoral necrosis and hemorrhage [4], [6], [7]. Especially, intratumoral hemorrhage is often observed even if the tumor size is small [2]. In our case, R2* map obtained from IDEAL IQ clearly revealed this hemorrhagic nature of this small lesion. IDEAL-IQ (GE, Milwaukee, WI) is a newly developed multiecho 3D Dixon's method, with which quantitative fat image and R2* map can be simultaneously obtained under breath-holding, by means of correcting several confounding factors including T2* decay, T1 bias, B0 inhomogeneity, eddy currents, and multipeak fat spectra [8], [9], [10], [11], [12]. Because iron is the most common substance that causes R2* elevation or T2* shortening, high signal on R2* map is indicative of the presence of hemosiderin [9], [10], [11], [12], a degraded substance of hemorrhage. Similar observation has recently been reported using T2*-weighted images for this entity [14]. This elevated R2* is considered the cause of hypointensity of the lesion on diffusion-weighted images, whereas there was apparent accumulation of FDG at the lesion on PET/CT. Another point in our case was the intraluminal growth pattern of the tumor without macroscopic parenchymal component. To the best of our knowledge, 4 cases of small UCPOGCs with predominant intraductal growth and without macroscopic extraductal mass formation have been reported [1], [3], [6], [15]. Recently, Muraki et al revealed that UCPOGC often show intraductal growth pattern (40%), which may suggest relatively indolent biological behavior of this entity [3], [7]. Differential diagnosis of tumors exhibiting this peculiar growth pattern includes intraductal papillo-tubular neoplasm, and intraductal papillary mucinous neoplasms (MD type), and NET, but small number of cases of acinar cell carcinoma and UCPOGC have been reported as well [1], [3], [4], [5], [15], [16], [17]. Because the lesion in the current report was apparently hypervascular, our preoperative diagnosis of NET was made. NET, however, usually grows into MPD continuously from distinct parenchymal primary lesion (namely, as tumor thrombus) and its intraductal component tends to show high signal intensity on T2-weighted images [18], [19], [13], which is discordant with the present case. Although R2* map is a useful tool to detect small amount of iron, it is based on sophisticated technology and is not necessarily available in every institute. On the other hand, chemical shift gradient-echo imaging is a basic sequence in clinical practice, and is now widely available. Because the echo time of the in-phase image is set longer than that of the out-of-phase image, significant signal loss on the in-phase image as compared to the out-of-phase image indicates T2* shortening effect, typically caused by the presence of iron deposits [20]. Actually this finding was confirmed in our case as well, and therefore, we believe this is a good and easy alternative to R2* map in routine clinical practice. In conclusion, radiologists should include UCPOGC in the differential diagnosis of intraluminal lesions located within MPD, particularly when its hemorrhagic nature is suggested on imaging, including R2* map.
  3 in total

1.  Osteoclast: like giant cell undiferrentiated pancreatic tumor diagnosed by means of EUS guided FNA.

Authors:  Alexandra Kalogeraki; Ioannis Mouzas; Ioannis E Koutroubakis; Eleni Moustou; Eleni Lappa; Dimitrios Tamiolakis; Aggeliki Machaira; Eleni Orfanoudaki; Evangelos Kalaitzakis
Journal:  Acta Biomed       Date:  2021-05-12

2.  Conversion surgery for undifferentiated carcinoma with osteoclast-like giant cells of the pancreas: a case report.

Authors:  Yosuke Igarashi; Takeshi Gocho; Tomohiko Taniai; Tadashi Uwagawa; Ryoga Hamura; Yoshihiro Shirai; Jungo Yasuda; Koichiro Haruki; Kenei Furukawa; Toru Ikegami
Journal:  Surg Case Rep       Date:  2022-03-14

3.  Undifferentiated Carcinoma of Pancreas with Osteoclast-Like Giant Cells: One Center's Experience of 13 Cases and Characteristic Pre-Operative Images.

Authors:  Yong Gao; Baobao Cai; Lingdi Yin; Guoxin Song; Zipeng Lu; Feng Guo; Jianmin Chen; Chunhua Xi; Jishu Wei; Junli Wu; Wentao Gao; Kuirong Jiang; Yi Miao
Journal:  Cancer Manag Res       Date:  2022-04-11       Impact factor: 3.602

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.